Skip to main content
PMC home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1997 Jan;87(1):10–12. doi: 10.2105/ajph.87.1.10

Janus considers the HIV pandemic--harnessing recent advances to enhance AIDS prevention.

M E St Louis, J N Wasserheit, H D Gayle
PMCID: PMC1380755  PMID: 9065212

Full text

PDF
11

Images in this article

11FIGURE 1
on p.11

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aral S. O., Holmes K. K., Padian N. S., Cates W., Jr Overview: individual and population approaches to the epidemiology and prevention of sexually transmitted diseases and human immunodeficiency virus infection. J Infect Dis. 1996 Oct;174 (Suppl 2):S127–S133. doi: 10.1093/infdis/174.supplement_2.s127. [DOI] [PubMed] [Google Scholar]
  2. Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Sáag M. S., Schooley R. T. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10;276(2):146–154. [PubMed] [Google Scholar]
  3. Collier A. C., Coombs R. W., Schoenfeld D. A., Bassett R. L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V. J. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996 Apr 18;334(16):1011–1017. doi: 10.1056/NEJM199604183341602. [DOI] [PubMed] [Google Scholar]
  4. Corey L., Holmes K. K. Therapy for human immunodeficiency virus infection -- what have we learned? N Engl J Med. 1996 Oct 10;335(15):1142–1144. doi: 10.1056/NEJM199610103351509. [DOI] [PubMed] [Google Scholar]
  5. D'Aquila R. T., Hughes M. D., Johnson V. A., Fischl M. A., Sommadossi J. P., Liou S. H., Timpone J., Myers M., Basgoz N., Niu M. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med. 1996 Jun 15;124(12):1019–1030. doi: 10.7326/0003-4819-124-12-199606150-00001. [DOI] [PubMed] [Google Scholar]
  6. Fauci A. S. AIDS in 1996. Much accomplished, much to do. JAMA. 1996 Jul 10;276(2):155–156. [PubMed] [Google Scholar]
  7. Grosskurth H., Mosha F., Todd J., Mwijarubi E., Klokke A., Senkoro K., Mayaud P., Changalucha J., Nicoll A., ka-Gina G. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet. 1995 Aug 26;346(8974):530–536. doi: 10.1016/s0140-6736(95)91380-7. [DOI] [PubMed] [Google Scholar]
  8. Hammer S. M., Katzenstein D. A., Hughes M. D., Gundacker H., Schooley R. T., Haubrich R. H., Henry W. K., Lederman M. M., Phair J. P., Niu M. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996 Oct 10;335(15):1081–1090. doi: 10.1056/NEJM199610103351501. [DOI] [PubMed] [Google Scholar]
  9. Hayes R. J., Schulz K. F., Plummer F. A. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J Trop Med Hyg. 1995 Feb;98(1):1–8. [PubMed] [Google Scholar]
  10. Katzenstein D. A., Hammer S. M., Hughes M. D., Gundacker H., Jackson J. B., Fiscus S., Rasheed S., Elbeik T., Reichman R., Japour A. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996 Oct 10;335(15):1091–1098. doi: 10.1056/NEJM199610103351502. [DOI] [PubMed] [Google Scholar]
  11. Mellors J. W., Rinaldo C. R., Jr, Gupta P., White R. M., Todd J. A., Kingsley L. A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996 May 24;272(5265):1167–1170. doi: 10.1126/science.272.5265.1167. [DOI] [PubMed] [Google Scholar]
  12. Moss G. B., Overbaugh J., Welch M., Reilly M., Bwayo J., Plummer F. A., Ndinya-Achola J. O., Malisa M. A., Kreiss J. K. Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis. 1995 Dec;172(6):1469–1474. doi: 10.1093/infdis/172.6.1469. [DOI] [PubMed] [Google Scholar]
  13. O'Brien W. A., Hartigan P. M., Martin D., Esinhart J., Hill A., Benoit S., Rubin M., Simberkoff M. S., Hamilton J. D. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996 Feb 15;334(7):426–431. doi: 10.1056/NEJM199602153340703. [DOI] [PubMed] [Google Scholar]
  14. Wasserheit J. N. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992 Mar-Apr;19(2):61–77. [PubMed] [Google Scholar]
  15. Welles S. L., Jackson J. B., Yen-Lieberman B., Demeter L., Japour A. J., Smeaton L. M., Johnson V. A., Kuritzkes D. R., D'Aquila R. T., Reichelderfer P. A. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996 Oct;174(4):696–703. doi: 10.1093/infdis/174.4.696. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES